Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Adicionar filtros








Intervalo de ano
1.
Scientific Journal of Kurdistan University of Medical Sciences. 2008; 13 (1): 13-20
em Persa | IMEMR | ID: emr-94513

RESUMO

This randomized double-blind, placebo controlled study was performed to evaluate the effectiveness of gabapentin in the treatment of opiate withdrawal symptoms. This was a 3-week double-blind, randomized, placebo-controlled trial and performed in specialized addiction behavior unit, an outpatient unit for the treatment of patients with addiction in Isfahan. The study included forty patients, 37 males and 3 females, between 21-61 years of age who met DSM-IV criteria for opium dependence. The subjects were randomly assigned into 2 groups. The experimental group received MAD [methadone-assisted detoxification] and gabapentin 900 mg/day. Severity of different withdrawal symptoms was measured by using subjective opiate withdrawal scale [SWOS] in six steps. Despite superiority of gabapentin to placebo in controlling some of withdrawal symptoms no significant difference was noticed between the two groups. Addition of 900 mg/day of gabapentin to MAD treatment regimen is not significantly superior to placebo in controlling opium withdrawal symptoms


Assuntos
Humanos , Masculino , Feminino , Aminas , Ácidos Cicloexanocarboxílicos , Ácido gama-Aminobutírico , Transtornos Relacionados ao Uso de Opioides , Analgésicos Opioides , Metadona , Método Duplo-Cego , Placebos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA